This grant aims to investigate how incretin mimetics affect cancer risk, focusing on mechanisms rather than short-term outcomes like weight loss, to attract scientific talent for preclinical and patient studies.
Funder: National Institutes of Health
Due Dates: January 7, 2027 (Closing date) | January 8, 2027 (Expiration)
Funding Amounts: Up to $275,000 in direct costs over 2 years, with no more than $200,000 in any year
Summary: Supports exploratory mechanistic research on how incretin mimetics influence cancer risk using animal models or human samples.
Key Information: Clinical trials, entirely in vitro projects, and primarily epidemiologic studies are not supported.
The National Cancer Institute (NCI), part of NIH, supports investigator-initiated pilot and exploratory studies examining how incretin mimetics influence cancer risk. The program emphasizes GLP-1 and dual GLP-1/GIP-1 receptor agonists and seeks to attract scientists studying these agents in other diseases into cancer biology. Its focus is cancer-risk mechanisms rather than shorter-term outcomes such as weight loss or diabetes control.
Research may examine immune, metabolic, hormonal, cytokine, or other signaling changes, cancer-specific effects, differences between population groups, or dose-dependent off-target effects. Projects must analyze biological samples from treated animals or humans. Animal studies require cancer endpoints, while human studies may use biomarkers clearly associated with cancer development. When feasible, investigators should connect mechanistic findings in animal cancer models with medication-related changes in humans.